Cutaneous T-cell Lymphoma

This case suggests that systemic IFN-γ can act as a trigger for pMF. Furthermore, the distinct cytokine profile highlights that the IL-23/IL-17/IL-8 axis may be a crucial mediator in the pathogenesis of pMF.

In vivo validation using a MyLa xenograft model demonstrated significant tumor growth inhibition following G-1 treatment without toxicity. These findings position GPER as a promising therapeutic target in CTCL, and support further development of GPER-targeted strategies for treating CTCL.

P=N/A, N=350, Not yet recruiting, Caja Costarricense de Seguro Social

P1, N=72, Not yet recruiting, Kyowa Kirin, Inc. | N=34 --> 72

Both JAK1 and JAK3 play a role in the pathogenesis of MF. JAK1 may have a pathogenic role, particularly in the early stage of cutaneous T-cell lymphoma. This potentiates the idea of using JAK1 and JAK3 inhibitors for MF treatment.

We hypothesize that IL-17 inhibitors may promote the progression of MF by impairing anti-tumor immune responses and disrupting the Treg/Th17 balance. In psoriasis patients with atypical clinical manifestations or poor response to biologic therapy, the possibility of MF should be considered, and a skin biopsy is recommended prior to treatment when necessary to establish a definitive diagnosis.

P1/2, N=37, Not yet recruiting, Shanghai Jiao Tong University School of Medicine

P1/2, N=200, Recruiting, Dren Bio | N=69 --> 200

Recent years have seen a shift away from chemotherapy with the approval of targeted therapies like mogamulizumab, brentuximab vedotin, and denileukin diftitox-cxdl. Though these novel agents have improved outcomes for patients with advanced-stage CTCL, most patients will continue to experience relapses. Emerging agents, including lacutamab, resminostat, and immune checkpoint inhibitors and biomarkers including CD5, CD70, and CD47/Sirpα represent the next frontier in maintaining durable remissions and improving quality of life (QoL) for these patients.

Although clinical characteristics were comparable across age groups, geriatric patients showed differences in reported histopathological and immunophenotypic features; these observations may facilitate clinicopathological recognition of early-stage MF in older individuals. However, some features (particularly epidermal atrophy and superficial/papillary fibrosis) are not MF-specific and may partly reflect background age- and site-related changes.

Multiplex single-molecule fluorescence ISH confirmed the presence of MCPyV in CD4+ T-cells. These findings support the hypothesis that MCPyV infection is specifically associated with rare CD4+ T-cell lymphomas, particularly in transplant recipients.

P2, N=386, Not yet recruiting, Virogen Biotechnology Inc.